Karyopharm Therapeutics (KPTI) 주식 개요
상업화 단계의 제약 회사인 카리오팜 테라퓨틱스는 미국에서 암 및 기타 질병 치료를 위한 핵 수출용 의약품을 발굴, 개발 및 상용화하는 회사입니다. 자세히 보기
KPTI Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Karyopharm Therapeutics Inc. 경쟁사
가격 이력 및 성과
| 과거 주가 | |
|---|---|
| 현재 주가 | US$9.46 |
| 52주 최고가 | US$10.99 |
| 52주 최저가 | US$3.65 |
| 베타 | 0.82 |
| 1개월 변동 | 5.46% |
| 3개월 변동 | 72.63% |
| 1년 변동 | 110.69% |
| 3년 변동 | -65.54% |
| 5년 변동 | -94.07% |
| IPO 이후 변동 | -96.07% |
최근 뉴스 및 업데이트
내러티브 업데이트 • Jun 24
KPTI: Phase 3 Myelofibrosis Data Will Shape 2026 Risk Reward Profile
Analysts have adjusted their outlook on Karyopharm Therapeutics with a revised consensus price target, reflecting shifts in recent $5 and $8 upward revisions and $7 and $4 downward revisions as they reassess the company's risk profile and long term earnings potential. Analyst Commentary Recent Street research on Karyopharm Therapeutics shows a split view, with some firms revising price targets upward and others marking them down.Seeking Alpha • Jun 18
Karyopharm: Xpovio Revenue Stagnation And Toxicity Concerns Justify Sell
Summary Karyopharm Therapeutics receives a reiterated Sell rating due to persistent clinical and commercial challenges with selinexor (Xpovio). Xpovio revenues remain stagnant at $115 million, with ongoing toxicity and competition issues undermining growth and adoption. Recent Phase 3 SENTRY trial results for selinexor in myelofibrosis were mixed, missing key symptom improvement endpoints and highlighting severe adverse events. KPTI faces a thin balance sheet, ongoing cash burn, high dilution risk, and a pipeline still heavily reliant on selinexor with limited near-term catalysts. Read the full article on Seeking Alpha내러티브 업데이트 • Jun 07
KPTI: Phase 3 Myelofibrosis Data Will Drive 2026 Frontline Opportunity
Analysts have revised their price target on Karyopharm Therapeutics, citing updated views on fair value, growth, and profitability assumptions. The new target is $13.50, compared with the prior $15.33.Recent updates
내러티브 업데이트 • Jun 24
KPTI: Phase 3 Myelofibrosis Data Will Shape 2026 Risk Reward Profile
Analysts have adjusted their outlook on Karyopharm Therapeutics with a revised consensus price target, reflecting shifts in recent $5 and $8 upward revisions and $7 and $4 downward revisions as they reassess the company's risk profile and long term earnings potential. Analyst Commentary Recent Street research on Karyopharm Therapeutics shows a split view, with some firms revising price targets upward and others marking them down.Seeking Alpha • Jun 18
Karyopharm: Xpovio Revenue Stagnation And Toxicity Concerns Justify Sell
Summary Karyopharm Therapeutics receives a reiterated Sell rating due to persistent clinical and commercial challenges with selinexor (Xpovio). Xpovio revenues remain stagnant at $115 million, with ongoing toxicity and competition issues undermining growth and adoption. Recent Phase 3 SENTRY trial results for selinexor in myelofibrosis were mixed, missing key symptom improvement endpoints and highlighting severe adverse events. KPTI faces a thin balance sheet, ongoing cash burn, high dilution risk, and a pipeline still heavily reliant on selinexor with limited near-term catalysts. Read the full article on Seeking Alpha내러티브 업데이트 • Jun 07
KPTI: Phase 3 Myelofibrosis Data Will Drive 2026 Frontline Opportunity
Analysts have revised their price target on Karyopharm Therapeutics, citing updated views on fair value, growth, and profitability assumptions. The new target is $13.50, compared with the prior $15.33.
내러티브 업데이트 • May 03
KPTI: Selinexor Commercialization And Funding Pressures Will Likely Constrain Future Upside
Analyst price targets for Karyopharm Therapeutics have shifted, with recent cuts and a subsequent $8 increase tied to reassessments of revenue potential, profit margins and future P/E assumptions around selinexor and the broader pipeline. Analyst Commentary Recent Street research on Karyopharm Therapeutics shows a mixed picture, with one price target increase following several cuts over a relatively short window.내러티브 업데이트 • Apr 19
KPTI: Funding Uncertainty And Execution Risks Will Likely Cap Future Returns
Analysts have trimmed their average price target on Karyopharm Therapeutics by several dollars, citing updated views on discount rates, revenue assumptions and long term profit margins following recent Street research. Analyst Commentary Recent Street research shows several bearish analysts cutting their Karyopharm price targets by mid single digit to high single digit dollar amounts, pointing to revised assumptions on discount rates, revenue potential and long term margins.내러티브 업데이트 • Apr 04
KPTI: Funding Strains And Execution Risks Will Likely Restrain Future Upside
The Street’s blended fair value estimate for Karyopharm has been trimmed by $1.00 to $5.00, as analysts fold in lower projected revenue growth, a slightly softer profit margin outlook, a higher discount rate, and updated P/E assumptions following recent target cuts from multiple firms. Analyst Commentary Recent Street research has tilted more cautious on Karyopharm, with multiple bearish analysts cutting price targets and reassessing the risk profile around execution, profitability, and the timing and scale of future revenue contributions.내러티브 업데이트 • Mar 21
KPTI: Phase 1 Myelofibrosis Data Will Support 2026 Frontline Opportunity
Analysts have adjusted their price target for Karyopharm Therapeutics to $28, citing confidence in selinexor's differentiated mechanism of action, compelling Phase 1 data in myelofibrosis, and a projected peak revenue opportunity of $800m to $850m in frontline myelofibrosis, with further potential from multiple myeloma programs. Analyst Commentary Bullish Takeaways Bullish analysts see selinexor's differentiated mechanism of action as a key driver for long term value, supporting the $28 price target as they factor in a distinct clinical profile within myelofibrosis.
내러티브 업데이트 • Mar 07
KPTI: Refreshed Revenue And Margin Outlook Will Support Bullish Repricing
Analysts have updated their price target on Karyopharm Therapeutics from $66.25 to $23.00, citing refreshed assumptions around revenue growth, profit margins, discount rate, and future P/E following recent bullish Street research. Analyst Commentary Bullish analysts are framing the reset in price target to $23.00 as part of a broader constructive view on Karyopharm Therapeutics, where refreshed modeling assumptions are more closely aligned with recent positive Street research.내러티브 업데이트 • Feb 20
KPTI: Execution And Funding Risks Will Likely Cap Bullish Repricing
Analysts have raised their $6.00 price target for Karyopharm Therapeutics, citing slightly lower perceived risk, a modestly stronger revenue outlook, and a small increase in the expected future P/E as the key factors behind the update. Analyst Commentary Recent research commentary around Karyopharm Therapeutics has centered on how much risk investors should assign to the story, how sustainable the current revenue trajectory may be, and what a reasonable P/E might look like given execution needs ahead.내러티브 업데이트 • Feb 06
KPTI: Lower Risk View Will Support 2026 Myelofibrosis Phase III Milestone
Analysts have modestly raised their price target on Karyopharm Therapeutics to US$15.33, citing a slightly lower required return and similar long term growth and margin assumptions that keep the fair value estimate steady. Analyst Commentary Recent Street research has focused on how the updated price target for Karyopharm Therapeutics lines up with its risk profile and execution needs, rather than materially changing long term growth or margin assumptions.내러티브 업데이트 • Jan 23
KPTI: Extended Cash Runway Will Support 2026 Myelofibrosis Phase III Milestone
Narrative update on Karyopharm Therapeutics Analysts have nudged their fair value estimate for Karyopharm Therapeutics higher from US$14.67 to US$15.33, citing recent Street research that points to steady Xpovio sales, reduced financing overhangs, maintained MF timelines into March 2026, and updated price targets that reflect the latest financing transactions. Analyst Commentary Recent Street research highlights a mix of optimism around execution and caution around financing and valuation as analysts update their views on Karyopharm Therapeutics.분석 기사 • Jan 11
Karyopharm Therapeutics Inc.'s (NASDAQ:KPTI) Prospects Need A Boost To Lift Shares
You may think that with a price-to-sales (or "P/S") ratio of 1.1x Karyopharm Therapeutics Inc. ( NASDAQ:KPTI ) is...내러티브 업데이트 • Jan 09
KPTI: Financing Overhangs Will Likely Outweigh MF Timeline Support
Analysts have trimmed their 12 month price target on Karyopharm Therapeutics to US$19 from US$30, citing recent financing transactions. They also point to solid Xpovio sales and maintained MF timelines into March 2026 as support for the stock’s overall risk and reward profile.내러티브 업데이트 • Dec 25
KPTI Extended Cash Runway Will Likely Be Outweighed By Dilution Risk
Analysts have cut their price target on Karyopharm Therapeutics to about $6 from roughly $8 per share, citing the impact of recent financing transactions on valuation. At the same time, extended cash runway, solid Xpovio sales and visibility into key 2026 myelofibrosis data support a still constructive risk and reward profile.내러티브 업데이트 • Dec 11
KPTI: Extended Cash Runway Will Support Pivotal 2026 Myelofibrosis Phase III Readout
Analysts have modestly reduced their price targets on Karyopharm Therapeutics, trimming expectations from a prior average in the low $20s to the high teens. Recent financing transactions extend the cash runway into 2026 and also dilute near term upside, despite a solid outlook for Xpovio sales and key myelofibrosis data in 2026.내러티브 업데이트 • Nov 27
KPTI: Extended Cash Runway Will Support Key Myelofibrosis Phase III Data
Analysts have lowered their price targets on Karyopharm Therapeutics, with reductions such as $19 from $30 and $6 from $8. They cite the impact of recent financing transactions while maintaining positive views on the company's risk profile and its cash runway extension, which is expected to support upcoming trial milestones.내러티브 업데이트 • Nov 11
KPTI: Upcoming Myelofibrosis Phase III Readout Will Drive Future Opportunity
Karyopharm Therapeutics’ analyst fair value price target has decreased by $1.00 to $14.67. Analysts cite recent financing transactions and updated growth forecasts as key factors behind the revision.내러티브 업데이트 • Oct 28
Extended Cash Runway Will Support Pivotal Phase III Clinical Milestones
Karyopharm Therapeutics' analyst price target has been reduced sharply from approximately $23.07 to $15.67 per share. Analysts cite the company’s recent strategic financing measures and updated projections following extended cash runway and upcoming clinical milestones.내러티브 업데이트 • Oct 13
Phase III Trials And Global Partnerships Will Advance Personalized Medicine
Karyopharm Therapeutics' analyst price target has been reduced from $8 to $6. This reflects analysts' views that, while strategic financing has extended the company's cash runway into Q2 2026, financial constraints and the timeline to key clinical trial readouts warrant a tempered outlook.분석 기사 • Sep 11
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Held Back By Insufficient Growth Even After Shares Climb 65%
Karyopharm Therapeutics Inc. ( NASDAQ:KPTI ) shares have had a really impressive month, gaining 65% after a shaky...내러티브 업데이트 • Aug 15
Phase III Trials And Global Partnerships Will Advance Personalized Medicine
Karyopharm Therapeutics’ net profit margin has improved and its future P/E has declined—indicating stronger profitability and a more attractive valuation—while the consensus analyst price target remains unchanged at $25.92. What's in the News Provided 2025 earnings guidance, expecting total revenue between $140 million and $155 million, including U.S. XPOVIO net product and partner-derived revenue.분석 기사 • Aug 14
US$25.92: That's What Analysts Think Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Is Worth After Its Latest Results
NasdaqGS:KPTI 1 Year Share Price vs Fair Value Explore Karyopharm Therapeutics's Fair Values from the Community and...분석 기사 • May 24
Investors Don't See Light At End Of Karyopharm Therapeutics Inc.'s (NASDAQ:KPTI) Tunnel And Push Stock Down 27%
Unfortunately for some shareholders, the Karyopharm Therapeutics Inc. ( NASDAQ:KPTI ) share price has dived 27% in the...분석 기사 • May 22
Here's Why Shareholders May Want To Be Cautious With Increasing Karyopharm Therapeutics Inc.'s (NASDAQ:KPTI) CEO Pay Packet
Key Insights Karyopharm Therapeutics' Annual General Meeting to take place on 28th of May CEO Richard Paulson's total...
새로운 내러티브 • Apr 08
Phase III SENTRY And XPOVIO Approvals Will Secure Future Success
Positive trial outcomes in myelofibrosis and endometrial cancer could significantly boost revenue and redefine care standards.분석 기사 • Dec 24
Lacklustre Performance Is Driving Karyopharm Therapeutics Inc.'s (NASDAQ:KPTI) 27% Price Drop
Karyopharm Therapeutics Inc. ( NASDAQ:KPTI ) shareholders won't be pleased to see that the share price has had a very...분석 기사 • Oct 01
Why Investors Shouldn't Be Surprised By Karyopharm Therapeutics Inc.'s (NASDAQ:KPTI) Low P/S
You may think that with a price-to-sales (or "P/S") ratio of 0.7x Karyopharm Therapeutics Inc. ( NASDAQ:KPTI ) is...분석 기사 • Aug 09
Karyopharm Therapeutics Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Shareholders might have noticed that Karyopharm Therapeutics Inc. ( NASDAQ:KPTI ) filed its second-quarter result this...주주 수익률
| KPTI | US Biotechs | US 시장 | |
|---|---|---|---|
| 7D | 4.9% | 4.6% | -2.5% |
| 1Y | 110.7% | 36.5% | 20.1% |
수익률 대 산업: KPTI은 지난 1년 동안 36.5%의 수익을 기록한 US Biotechs 산업보다 더 좋은 성과를 냈습니다.
수익률 대 시장: KPTI은 지난 1년 동안 20.1%를 기록한 US 시장보다 더 좋은 성과를 냈습니다.
주가 변동성
| KPTI volatility | |
|---|---|
| KPTI Average Weekly Movement | 10.9% |
| Biotechs Industry Average Movement | 10.6% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.1% |
안정적인 주가: KPTI는 지난 3개월 동안 US 시장에 비해 주가 변동성이 크지 않았습니다.
시간에 따른 변동성: KPTI의 주간 변동성(11%)은 지난 1년 동안 안정적이었습니다.
회사 소개
| 설립 | 직원 수 | CEO | 웹사이트 |
|---|---|---|---|
| 2008 | 228 | Richard Paulson | www.karyopharm.com |
상업화 단계의 제약 회사인 Karyopharm Therapeutics는 미국에서 암 및 기타 질병 치료를 위해 핵 수출을 억제하는 약물을 발견, 개발 및 상업화하는 회사입니다. 이 회사는 핵수출 단백질 엑스포틴 1(XPO1)을 억제하는 새로운 저분자 선택적 핵수출 억제제(SINE) 화합물을 발견, 개발 및 상업화합니다. 주요 화합물로는 성인 다발성 골수종 환자 치료를 위한 보르테조밉 및 덱사메타손과 병용하는 엑스포비오, 재발성 또는 불응성 다발성 골수종 성인 환자 치료를 위한 덱사메타손과 병용, 재발성 또는 불응성 미만성 거대 B세포 림프종(DLBCL) 성인 환자 치료를 위한 엑스포비오 등이 있습니다.
Karyopharm Therapeutics Inc. 기초 지표 요약
| KPTI 기초 통계 | |
|---|---|
| 시가총액 | US$206.69m |
| 순이익 (TTM) | -US$194.97m |
| 매출 (TTM) | US$151.12m |
1.4x
주가매출비율(P/S)-1.1x
주가수익비율(P/E)KPTI는 고평가되어 있습니까?
공정 가치 및 평가 분석 보기순이익 및 매출
| KPTI 손익계산서 (TTM) | |
|---|---|
| 매출 | US$151.12m |
| 매출원가 | US$130.79m |
| 총이익 | US$20.33m |
| 기타 비용 | US$215.30m |
| 순이익 | -US$194.97m |
최근 보고된 실적
Mar 31, 2026
다음 실적 발표일
해당 없음
| 주당순이익(EPS) | -8.60 |
| 총이익률 | 13.45% |
| 순이익률 | -129.02% |
| 부채/자본 비율 | -111.7% |
KPTI의 장기 실적은 어땠습니까?
과거 실적 및 비교 보기기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/06/25 01:02 |
| 종가 | 2026/06/25 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Karyopharm Therapeutics Inc.는 20명의 분석가가 다루고 있습니다. 이 중 7명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Colleen Kusy | Baird |
| Ying Huang | BofA Global Research |
| Harshita Polishetty | B. Riley Securities, Inc. |